AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01706263
Drug: MAXCLARITY II (2.5% BPO) Foam Cleanser
RxNorm normalized name: PERI-WASH II CLEANSER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available over the counter.
Trial: NCT01706263
Drug: MAXCLARITY II (2.5% BPO) Foam Treatment
RxNorm normalized name: MaxClarity 2.5 % Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available over the counter.
Trial: NCT02310763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546024
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
Trial: NCT00559364
Drug: Viokase® 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Trial: NCT00559364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
Trial: NCT00559364
Drug: Proton pump inhibitor (PPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
Trial: NCT04126343
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding
Trial: NCT01358084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Trial: NCT01004445
Drug: Amikacin (BAY41-6551)
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
Trial: NCT01004445
Drug: Amikacin (BAY41-6551)
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
Trial: NCT01004445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two aerosol treatments per day (one treatment every 12hr)
Trial: NCT01118845
Drug: SyB L-0501
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.
Trial: NCT02615587
Drug: Standard of care in AF in Denmark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As used in clinical practice, analysed as per drug class, not separate drugs.
Trial: NCT04440280
Drug: N-acetyl cysteine (NAC) 10% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
Trial: NCT04440280
Drug: N-acetyl cysteine (NAC) 20% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
Trial: NCT01731886
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
Trial: NCT02289690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to veliparib administered orally twice a day according to the dosing schedule.
Trial: NCT03712124
Drug: CNSA-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNSA-001 Powder for Suspension
Trial: NCT03712124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Suspension
Trial: NCT04674709
Drug: Oleander 4X - single
RxNorm normalized name: NERIUM OLEANDER FLOWER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
Trial: NCT04674709
Drug: Oleander 4X - double
RxNorm normalized name: NERIUM OLEANDER FLOWER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
Trial: NCT04674709
Drug: Oleander 4X - quadruple
RxNorm normalized name: NERIUM OLEANDER FLOWER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
Trial: NCT04674709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
Trial: NCT01310361
Drug: Intramuscular Benzathin Penicillin G
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
Trial: NCT01899326
Drug: Desipramine Hydrochloride
RxNorm normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03573817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo version of Revefenacin is administered via a nebulizer.
Trial: NCT04273217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
Trial: NCT01396421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, for six weeks
Trial: NCT03182751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Looks exactly like the study drug, but it contains no active ingredient
Trial: NCT00957216
Drug: Placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 2 wafers 4 times a day
Trial: NCT00503113
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg intravenous (iv) injection every 3 months
Trial: NCT00503113
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg intravenous (iv) infusion every 3 months
Trial: NCT04644627
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical gentamicin ointment on wounds once daily for 6 weeks
Trial: NCT00820508
Drug: CHR-2845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
Trial: NCT00329160
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5-20 mg
Trial: NCT00329160
Drug: HMG CoA inhibitor
RxNorm normalized name: HMG CoA reductase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hydroxy-3-methylglutaryl-coenzyme A
Trial: NCT03135340
Drug: WALANT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
Trial: NCT03135340
Drug: Regional Anesthetic Injection
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
Trial: NCT04491916
Drug: irone sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
Trial: NCT00401245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering placebo
Trial: NCT01230645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Trial: NCT00230594
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
Trial: NCT00891072
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04920370
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuPH20 will be administered via SC route.
Trial: NCT04920370
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via SC route.
Trial: NCT04920370
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via IV route.
Trial: NCT01247740
Drug: NuTRIflex Lipid peri
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parenteral nutrition
Trial: NCT01374620
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days
Trial: NCT00664287
Drug: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
Trial: NCT02333188
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02333188
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00623636
Drug: MAP0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
Trial: NCT00623636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
Trial: NCT03838341
Drug: Oral anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
Trial: NCT02451306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See information in arm description.
Trial: NCT01959490
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01959490
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04500132
Drug: Placebo EC-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo EC-18 QD
Trial: NCT02842021
Drug: S2G6T-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day topical cream
Trial: NCT01780480
Drug: Dynamic Chinese herbal granule formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
Trial: NCT02842021
Drug: S2G6T-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day topical cream
Trial: NCT02842021
Drug: S2G6T-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day topical cream
Trial: NCT02842021
Drug: S2G6T-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day topical cream
Trial: NCT00872157
Drug: BMTP-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
Trial: NCT01780480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
Trial: NCT02849236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL saline 0.9%
Trial: NCT02246764
Drug: AR-13324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop once daily (QD), PM, OU
Trial: NCT01170507
Drug: Placebo orally daily for 5 months
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02246764
Drug: AR-13324 Ophthalmic Solution 0.02% BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop BID, AM/PM, OU
Trial: NCT02335294
Drug: TRV130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue: Ibuprofen, oxycodone
Trial: NCT02335294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue: Ibuprofen, oxycodone
Trial: NCT03657238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single S.C. dose of placebo for subjects in placebo group
Trial: NCT02807441
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive different doses of aspirin perioperatively to assess bleeding association.
Trial: NCT00894842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Trial: NCT02347319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
Trial: NCT01115855
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
Trial: NCT01115855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily or every once daily
Trial: NCT02238132
Drug: ATROVENT® inhalets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02079675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
Trial: NCT04429867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
Trial: NCT00367016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given by subcutaneous injection.
Trial: NCT02457611
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT01254461
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x100 mg per oral, twice daily for 8 days
Trial: NCT01254461
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg, once daily at Day 1, period A and Day 8, period B
Trial: NCT03110380
Drug: DTG Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03110380
Drug: F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT03110380
Drug: B/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT01560884
Drug: Renazorb 4500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
Trial: NCT01560884
Drug: Renazorb 6000 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
Trial: NCT00869661
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg bid for 24 weeks
Trial: NCT00869661
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg bid for 12 weeks
Trial: NCT00869661
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg bid for 8 weeks
Trial: NCT00869661
Drug: RO5024048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg bid for 12 weeks
Trial: NCT01908205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00640458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01845116
Drug: Omegaven®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Trial: NCT01355302
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Trial: NCT01712451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02091310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02091310
Drug: GFT505
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00490854
Drug: Human Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient specific, inhaled, at meals, 76 weeks
Trial: NCT04087317
Drug: Paracetamol 1000 Mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Trial: NCT04087317
Drug: Ibuprofen 400Mg Tab
RxNorm normalized name: IBUPROFEN 400MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Trial: NCT04087317
Drug: Paracetamol 1000 Mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Trial: NCT04087317
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Trial: NCT04087317
Drug: MIR
RxNorm normalized name: Miraa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
Trial: NCT04385095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via inhalation
Trial: NCT01283646
Drug: Apevitin BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 to 5 ml 3 times a daily
Trial: NCT00004988
Drug: VNP20009
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00436917
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid
Trial: NCT00808509
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At least 10 mg/week administered orally or subcutaneously
Trial: NCT00587431
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
Trial: NCT00196820
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes